304 related articles for article (PubMed ID: 17977644)
1. Pasireotide (SOM230): development, mechanism of action and potential applications.
Schmid HA
Mol Cell Endocrinol; 2008 May; 286(1-2):69-74. PubMed ID: 17977644
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
Pöll F; Lehmann D; Illing S; Ginj M; Jacobs S; Lupp A; Stumm R; Schulz S
Mol Endocrinol; 2010 Feb; 24(2):436-46. PubMed ID: 20051480
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
9. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide - Mechanism of Action and Clinical Applications.
Sawicka-Gutaj N; Owecki M; Ruchala M
Curr Drug Metab; 2018; 19(10):876-882. PubMed ID: 29595102
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
12. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide-a novel somatostatin receptor ligand after 20 years of use.
Bolanowski M; Kałużny M; Witek P; Jawiarczyk-Przybyłowska A
Rev Endocr Metab Disord; 2022 Jun; 23(3):601-620. PubMed ID: 35067849
[TBL] [Abstract][Full Text] [Related]
14. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
15. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies.
van Hoek M; Hofland LJ; de Rijke YB; van Nederveen FH; de Krijger RR; van Koetsveld PM; Lamberts SW; van der Lely AJ; de Herder WW; Feelders RA
J Clin Endocrinol Metab; 2009 Feb; 94(2):428-33. PubMed ID: 19017754
[TBL] [Abstract][Full Text] [Related]
16. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
Nolan LA; Schmid HA; Levy A
Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
[TBL] [Abstract][Full Text] [Related]
17. Pasireotide: a review of its use in Cushing's disease.
McKeage K
Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
[TBL] [Abstract][Full Text] [Related]
18. Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly.
Fukunaga K; Imachi H; Sato S; Kobayashi T; Yoshioka Y; Saheki T; Ban N; Urushihara K; Lyu J; Dong T; Ishikawa R; Kadota K; Haba R; Inoshita N; Murao K
Intern Med; 2021 Apr; 60(7):1047-1053. PubMed ID: 33162471
[TBL] [Abstract][Full Text] [Related]
19. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
[TBL] [Abstract][Full Text] [Related]
20. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
Gatto F; Arvigo M; Amarù J; Campana C; Cocchiara F; Graziani G; Bruzzone E; Giusti M; Boschetti M; Ferone D
Pituitary; 2019 Feb; 22(1):89-99. PubMed ID: 30483918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
